# Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Canonical URL: https://biopharmsignal.com/news/ANNX/annexon-reports-first-quarter-2026-financial-results-portfolio-progress-and-key-anticipated-milestones
Ticker: ANNX
Company: Annexon, Inc.
Source: Annexon, Inc.
Published: 2026-05-07 20:01 EST
Original Source URL: https://ir.annexonbio.com
## Summary

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré

## Article Body
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré
## Recent Company News
- 2026-05-27 12:00 EST — [Annexon to Participate in Upcoming June Investor Conferences](https://biopharmsignal.com/news/ANNX/annexon-to-participate-in-upcoming-june-investor-conferences) — Source: Annexon, Inc.
- 2026-05-07 20:01 EST — [Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones](https://biopharmsignal.com/news/ANNX/annexon-reports-first-quarter-2026-financial-results-portfolio-progress-and-key-anticipated-milestones) — Source: Annexon, Inc.
- 2026-05-06 12:00 EST — [Annexon to Present at the Bank of America Securities Health Care Conference 2026](https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-bank-of-america-securities-health-care-conference-2026) — Source: Annexon, Inc.
- 2026-04-08 20:05 EST — [Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/ANNX/annexon-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Annexon, Inc.
- 2026-03-30 20:01 EST — [Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones](https://biopharmsignal.com/news/ANNX/annexon-reports-fourth-quarter-and-year-end-2025-financial-results-portfolio-progress-and-key-anticipated-milestones) — Source: Annexon, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)